China has become one of the most important markets for pharma companies, given the vast patient population and the rising cancer rates, and western pharmaceutical companies are making greater inroads there.
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
Whatever comes out of Congress on the “repeal and replace” of the Affordable Care Act (ACA or Obamacare) matters because it will affect the bottom line of the life sciences industry as well as all of its industry partners.
Urovant Sciences, a Vivek Ramaswamy company under the Roivant umbrella, filed for an initial public offering (IPO) to raise $150 million.
The U.S. Food and Drug Administration announced a new pilot program aimed at stimulating the use of complex innovative clinical trial designs for drugs and biologics.
Among the industry group PhRMA’s findings was that overall R&D spending was at an all-time high in 2017, hitting $71.4 billion, up from $65.5 billion in 2016 and from $29.8 billion in 2001.
Mark Emalfarb – founder, chairman and chief executive officer of Jupiter, Florida-based Dyadic International – believes he knows how to revolutionize biopharma manufacturing.
There were plenty of interesting and important stories in the biopharma space during first-half 2018
Poietis and Prometheus entered into a two-year collaborative research agreement to develop high-precision 3D bioprinting of tissue engineered advanced therapeutic medicinal products for skeletal regeneration.
The tenth annual Dealmakers’ Intentions Study from Syneos Health Consulting, an industry-leading consulting firm specializing in the biopharmaceutical industry, concludes that the dealmaking environment will continue to accelerate with buyers becoming more selective in ensuring they have the most appropriate assets and corresponding deals in place.
Imbruvica Plus Gazyva Phase 3 iLLUMINATE Trial for First-Line Therapy of Chronic Lymphocytic Leukemia Patients Met Primary Endpoint
AbbVie, a research-based global biopharmaceutical company, announced that the Phase 3 iLLUMINATE (PCYC-1130) trial met its primary endpoint of improvement in progression-free survival.
Sangamo Therapeutics recently filed a notice with the U.S. SEC describing a data security breach.